| Abstract [eng] |
Introduction. It is well known that the combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is an optimal treatment method managing such diseases as primary peritoneal tumours or peritoneal carcinomatosis from appendiceal cancer. However, there is a shortage of publications that would analyse the results of using this technique on such patients. The aim of our study is to evaluate the data of people treated for these specified diseases. Materials and methods. A restrospective analysis was performed on the data of patients treated in VUL SK during 2011-2021 years for primary peritoneal tumours or peritoneal carcinomatosis from appendiceal cancer. Overall, 21 patients’ perioperative data was analysed. Disease-free, overall survival and factors that might have had an impact on them. Clinical variables’ correlation between themselves was also analysed. All the calculations were performed using SPSS for Windows version 26. Foundings were considered statistically significant when p value was lower or equal to 0,05. Results. Most of the patients were female – 71,4% (n = 15). Mean age of all the patients was 61,24 (±11,29) years. Mean hospital stay was 23 (±12,22) days. Patients’ mean peritoneal carcinomatosis index (PCI) was 15,95 (±9,65). Mean operation duration was 522,38 (±161,95) minutes, mean blood loss – 323,81 (±186,83). 5 year overall survival was 82% and 5 year disease-free survival was 53%. None of the clinical variables had a statistically significant impact on patients’ survival. Conclusions. CRS and HIPEC is safe and feasible when treating primary peritoneal tumours or peritoneal carcinomatosis from appendiceal cancer. It ensures acceptable patient’s disease-free survival and good overall survival. Higher patients‘ PCI was associated with longer operative time, hospital stay and increased blood loss. Patients who experienced complications also spent more time hospitalized. |
